Cassava Sciences Inc vs Innodata Inc — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while Innodata Inc trades at $61.5 (market cap $2.05B). The key difference: Innodata Inc is far larger — about 42.9× Cassava Sciences Inc's market cap, and Innodata Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | INOD | |
|---|---|---|
Market Cap | $47.75M | $2.05B |
Sector | Health | Technology |
52-Week High | $4.64 | $121.50 |
52-Week Low | $0.87 | $34.45 |
Enterprise Value | -$34.93M | $1.80B |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
INOD trades at $61.47, down 1.21% today, but maintains strong technical support at $60-$62 levels with bullish oscillators and mixed moving averages. The company demonstrates robust fundamental performance with 58% year-over-year revenue growth in Q2 2026, beating earnings estimates for three consecutive quarters, and expanding profit margins to 14.66%. Recent AI-driven business developments and strong analyst coverage support the positive momentum.
INOD presents a compelling growth opportunity with accelerating AI services demand and consistent earnings outperformance, though premium valuation metrics (P/E 48.6, P/S 6.8) warrant caution. Key risks include customer concentration and competitive pressures in the rapidly evolving AI sector. Analyst consensus remains bullish with a $130 price target representing 111% upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →